IL291329B2 - Polypeptides that can be determined in matrix metalloproteinases and uses thereof - Google Patents
Polypeptides that can be determined in matrix metalloproteinases and uses thereofInfo
- Publication number
- IL291329B2 IL291329B2 IL291329A IL29132922A IL291329B2 IL 291329 B2 IL291329 B2 IL 291329B2 IL 291329 A IL291329 A IL 291329A IL 29132922 A IL29132922 A IL 29132922A IL 291329 B2 IL291329 B2 IL 291329B2
- Authority
- IL
- Israel
- Prior art keywords
- ser
- gly
- leu
- xaa
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882377P | 2013-09-25 | 2013-09-25 | |
| US201461971332P | 2014-03-27 | 2014-03-27 | |
| PCT/US2014/057523 WO2015048329A2 (en) | 2013-09-25 | 2014-09-25 | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL291329A IL291329A (en) | 2022-05-01 |
| IL291329B1 IL291329B1 (en) | 2025-09-01 |
| IL291329B2 true IL291329B2 (en) | 2026-01-01 |
Family
ID=51691175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291329A IL291329B2 (en) | 2013-09-25 | 2014-09-25 | Polypeptides that can be determined in matrix metalloproteinases and uses thereof |
| IL322893A IL322893A (en) | 2013-09-25 | 2014-09-25 | Polypeptides that can be determined in matrix metalloproteinases and uses thereof |
| IL244744A IL244744B (en) | 2013-09-25 | 2016-03-24 | Matrix metalloproteinase cleavable polypeptides and uses thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322893A IL322893A (en) | 2013-09-25 | 2014-09-25 | Polypeptides that can be determined in matrix metalloproteinases and uses thereof |
| IL244744A IL244744B (en) | 2013-09-25 | 2016-03-24 | Matrix metalloproteinase cleavable polypeptides and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150087810A1 (enExample) |
| EP (1) | EP3049111A2 (enExample) |
| JP (5) | JP6915987B2 (enExample) |
| KR (3) | KR20250051130A (enExample) |
| CN (3) | CN118165076A (enExample) |
| AU (4) | AU2014324884B2 (enExample) |
| CA (2) | CA2925106C (enExample) |
| IL (3) | IL291329B2 (enExample) |
| MX (2) | MX379106B (enExample) |
| NZ (2) | NZ718283A (enExample) |
| RU (1) | RU2715232C2 (enExample) |
| WO (1) | WO2015048329A2 (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| SG11201509595PA (en) | 2013-05-28 | 2015-12-30 | Dcb Usa Llc | Antibody locker for the inactivation of protein drug |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| HUE054131T2 (hu) | 2015-11-19 | 2021-08-30 | Revitope Ltd | Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| AU2017364818C1 (en) | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| CA3041279A1 (en) | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding domain, and polypeptide including conveying section |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| EP3551667A4 (en) | 2016-12-09 | 2020-06-17 | Seattle Genetics, Inc. | BIVALENT ANTIBODIES MASKED BY COILS |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| WO2018213335A1 (en) * | 2017-05-16 | 2018-11-22 | Scalmibio, Inc. | Activatable antibodies and methods of use thereof |
| CN107501394B (zh) * | 2017-06-19 | 2021-02-26 | 天津医科大学 | 高特异性mmp-14底物肽及其制备方法和应用 |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| WO2019036433A2 (en) | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| KR20200089312A (ko) | 2017-11-28 | 2020-07-24 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| KR20250134208A (ko) | 2017-11-28 | 2025-09-09 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드 |
| AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| CN112005304A (zh) | 2018-03-20 | 2020-11-27 | 西托姆克斯治疗公司 | 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法 |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| JP7428661B2 (ja) * | 2018-05-30 | 2024-02-06 | 中外製薬株式会社 | Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド |
| EP3816182A4 (en) | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| US10988491B2 (en) | 2018-08-17 | 2021-04-27 | Massachusetts Institute Of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| AU2019356573B2 (en) | 2018-10-11 | 2025-12-18 | Inhibrx Biosciences, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| JP2022512124A (ja) * | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス，インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| RS64961B1 (sr) | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| BR112021022666A2 (pt) * | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| EP3972982A1 (en) | 2019-05-20 | 2022-03-30 | Massachusetts Institute of Technology | Boronic ester prodrugs and uses thereof |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| CN113905757B (zh) | 2019-06-05 | 2026-01-13 | 中外制药株式会社 | 抗体切割位点结合分子 |
| TW202112801A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 純化遮蔽抗體之方法 |
| TW202112354A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2021141662A1 (en) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| WO2021207657A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| EP4297798A4 (en) * | 2021-02-25 | 2025-11-12 | Allygen Group | Targeting Conjugates Comprising Effector Molecules and Their Uses |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20240352080A1 (en) | 2021-07-14 | 2024-10-24 | Seagen Inc. | Antibody Masking Domains |
| US20230065782A1 (en) * | 2021-07-14 | 2023-03-02 | Oncoimmunin, Inc. | Targeted and localized in vivo delivery of oligonucleotides |
| WO2023034825A1 (en) | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| WO2023049825A1 (en) | 2021-09-24 | 2023-03-30 | Seagen Inc. | Improved antibody masking domains |
| MX2024004301A (es) | 2021-10-08 | 2024-04-26 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y metodos combinados. |
| WO2023060156A2 (en) | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| PE20241343A1 (es) | 2021-10-15 | 2024-07-03 | Cytomx Therapeutics Inc | Complejo polipeptidico activable |
| US20230174995A1 (en) | 2021-10-15 | 2023-06-08 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| EP4694934A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| KR20260056204A (ko) | 2023-08-14 | 2026-04-24 | 보로 테라퓨틱스, 인코포레이티드 | 표적 세포에 대한 골수 세포 활성을 조건부로 촉진시키는 치료용 결합제 및 이의 용도 |
| KR20260115591A (ko) * | 2023-10-19 | 2026-07-24 | 유노벨(상하이) 바이오파마 씨오 엘티디 | 폴리펩타이드, 생리활성 접합체, 이의 제조방법 및 용도 |
| CN122349537A (zh) | 2023-12-01 | 2026-07-07 | 阿布林克斯有限公司 | 识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体 |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026035650A2 (en) * | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
| WO2026112598A1 (en) | 2024-11-25 | 2026-05-28 | Modernatx, Inc. | Messenger rna encoding masked proteins and compositions and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009025846A2 (en) * | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2010081173A2 (en) * | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US20130150558A1 (en) * | 2008-12-08 | 2013-06-13 | John C. Williams | Design and development of masked therapeutic antibodies to limit off-target effects; application to anti-egfr antibodies |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| EP0904386A2 (en) * | 1996-05-10 | 1999-03-31 | Danisco A/S | alpha-GLUCURONIDASES OF ASPERGILLUS, PRODUCTION THEREOF AND THEIR USES |
| AUPO930697A0 (en) * | 1997-09-19 | 1997-10-09 | Walter And Eliza Hall Institute Of Medical Research, The | Catalytic antibodies and a method of producing same |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| ES2299244T3 (es) * | 1998-05-13 | 2008-05-16 | Domantis Limited | Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas. |
| WO2001055448A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| EP1328632A2 (en) | 2000-08-04 | 2003-07-23 | Eli Lilly And Company | C1q-related factor, homologous polypeptides and therapeutic uses thereof |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| WO2002038796A2 (en) | 2000-11-08 | 2002-05-16 | Beth Israel Deaconess Medical Center, Inc. | Methods for determining protease cleavage site motifs |
| US20030134298A1 (en) | 2001-07-03 | 2003-07-17 | Madison Edwin L. | Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon |
| US20050208602A1 (en) * | 2001-08-10 | 2005-09-22 | Rosen Craig A | 89 human secreted proteins |
| US7439319B2 (en) | 2001-09-14 | 2008-10-21 | Burnham Institute For Medical Research | Selective substrates for matrix metalloproteinases |
| WO2003038083A1 (en) | 2001-10-29 | 2003-05-08 | Bayer Healthcare Ag | Regulation of human type i adenylate cyclase |
| CA2475388A1 (en) | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| WO2004099254A2 (en) | 2003-05-06 | 2004-11-18 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US9079936B2 (en) * | 2003-07-01 | 2015-07-14 | University Of Maryland, Baltimore | Derivatives of APF and methods of use |
| WO2005090393A2 (en) | 2004-02-09 | 2005-09-29 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Multimeric protein toxins to target cells having multiple identifying characteristics |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| US7572444B2 (en) | 2004-12-20 | 2009-08-11 | Amgen Fremont Inc. | Binding proteins specific for human matriptase |
| AU2006235276A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | CACNA1E in cancer diagnosis, detection and treatment |
| WO2007027935A2 (en) | 2005-08-31 | 2007-03-08 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| KR101126423B1 (ko) | 2005-10-21 | 2012-07-11 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 보체 활성화를 억제하는 변형된 프로테아제 |
| EP1993608A1 (en) | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| PT2845866T (pt) * | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| CA2688434A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| CA2683801A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| DE102008034659A1 (de) * | 2008-07-25 | 2010-02-04 | Schmidt-Seeger Gmbh | Rundbehälter zum Keimen oder Darren von Getreide |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| WO2010088691A2 (en) * | 2009-02-02 | 2010-08-05 | Washington State University | Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| WO2010129609A2 (en) | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| MX2012002719A (es) * | 2009-09-02 | 2012-06-28 | Univ Kansas State | Ensayos opticos y de imagenes por resonancia magnetica (mri) para proteasas. |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US20110214205A1 (en) * | 2010-02-26 | 2011-09-01 | Monsanto Technology Llc. | Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits |
| BR112012029666A2 (pt) * | 2010-05-20 | 2020-10-06 | Allergan, Inc. | toxinas clostridiais degradáveis |
| PL391627A1 (pl) | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| EP2709666B1 (en) | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| RU2639526C2 (ru) | 2011-06-28 | 2017-12-21 | ИНХИБРКС ЭлЭлСи | Слитые полипептиды, содержащие домен wap, и способы их применения |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| SG11201408554QA (en) | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9487590B2 (en) * | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| WO2014107559A1 (en) | 2013-01-03 | 2014-07-10 | Branders.Com, Inc. | Methods and apparatus for determining a score value for criteria associated with a gift |
| JP6605957B2 (ja) | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス，インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| EP2988786A4 (en) | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE |
| SG11201509595PA (en) | 2013-05-28 | 2015-12-30 | Dcb Usa Llc | Antibody locker for the inactivation of protein drug |
| BR112015030514A2 (pt) | 2013-06-04 | 2017-08-29 | Cytomx Therapeutics Inc | Composições e métodos para conjugação de anticorpos ativáveis |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| BR112017023872A2 (pt) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| CN110072890B (zh) | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| JP2020511130A (ja) | 2017-03-09 | 2020-04-16 | サイトメックス セラピューティクス インコーポレイテッド | Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス，インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
-
2014
- 2014-09-25 KR KR1020257010278A patent/KR20250051130A/ko active Pending
- 2014-09-25 CN CN202410265535.5A patent/CN118165076A/zh active Pending
- 2014-09-25 IL IL291329A patent/IL291329B2/en unknown
- 2014-09-25 AU AU2014324884A patent/AU2014324884B2/en active Active
- 2014-09-25 CA CA2925106A patent/CA2925106C/en active Active
- 2014-09-25 CN CN202410265536.XA patent/CN118146306A/zh active Pending
- 2014-09-25 EP EP14783968.2A patent/EP3049111A2/en active Pending
- 2014-09-25 WO PCT/US2014/057523 patent/WO2015048329A2/en not_active Ceased
- 2014-09-25 CN CN201480064185.0A patent/CN106163556B/zh active Active
- 2014-09-25 US US14/497,089 patent/US20150087810A1/en not_active Abandoned
- 2014-09-25 NZ NZ718283A patent/NZ718283A/en unknown
- 2014-09-25 NZ NZ756892A patent/NZ756892A/en unknown
- 2014-09-25 KR KR1020237000930A patent/KR102790260B1/ko active Active
- 2014-09-25 JP JP2016516911A patent/JP6915987B2/ja active Active
- 2014-09-25 MX MX2016003957A patent/MX379106B/es unknown
- 2014-09-25 CA CA3214529A patent/CA3214529A1/en active Pending
- 2014-09-25 RU RU2016115542A patent/RU2715232C2/ru active
- 2014-09-25 KR KR1020167010749A patent/KR102488220B1/ko active Active
- 2014-09-25 IL IL322893A patent/IL322893A/en unknown
-
2016
- 2016-03-24 IL IL244744A patent/IL244744B/en unknown
- 2016-03-28 MX MX2021000416A patent/MX2021000416A/es unknown
-
2018
- 2018-11-02 US US16/179,670 patent/US11814410B2/en active Active
-
2019
- 2019-09-24 JP JP2019173550A patent/JP2020015749A/ja active Pending
-
2020
- 2020-06-12 AU AU2020203910A patent/AU2020203910B2/en active Active
-
2021
- 2021-05-10 JP JP2021080015A patent/JP2021138707A/ja not_active Withdrawn
-
2023
- 2023-07-27 JP JP2023122426A patent/JP2023159099A/ja active Pending
- 2023-09-25 US US18/474,134 patent/US12679899B2/en active Active
- 2023-09-25 US US18/474,103 patent/US12679898B2/en active Active
- 2023-10-25 AU AU2023254931A patent/AU2023254931B2/en active Active
-
2024
- 2024-10-23 JP JP2024186751A patent/JP7806174B2/ja active Active
-
2026
- 2026-04-09 AU AU2026202666A patent/AU2026202666A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009025846A2 (en) * | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| US20130150558A1 (en) * | 2008-12-08 | 2013-06-13 | John C. Williams | Design and development of masked therapeutic antibodies to limit off-target effects; application to anti-egfr antibodies |
| WO2010081173A2 (en) * | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291329B1 (en) | Polypeptides that can be determined in matrix metalloproteinases and uses thereof | |
| AU2010324684B2 (en) | Antibody Fc mutants with ablated effector functions | |
| EP3484925B1 (en) | Anti-tigit antibodies | |
| CN107011441B (zh) | 抗pd1抗体及其作为治疗剂与诊断剂的用途 | |
| US12497462B2 (en) | Anti-CD26 proteins and uses thereof | |
| US20230331824A1 (en) | Single-domain antibodies that bind sars-cov-2 | |
| KR20170035930A (ko) | Cd45 및 cd79에 대한 특이성을 갖는 분자 | |
| AU2015277379B2 (en) | Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells | |
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
| CN120731225A (zh) | Il-2融合蛋白 | |
| CN121717905A (zh) | 抗-pd-1抗体 | |
| JP2023507277A (ja) | 多特異性抗体 | |
| WO2025041101A1 (en) | Activatable il-18 immunocytokines and uses thereof | |
| AU2021200190B2 (en) | Antibody Fc mutants with ablated effector functions | |
| CN105037553A (zh) | 一种能够检测癌症的免疫球蛋白 | |
| CN119798442A (zh) | 特异性结合cd39的纳米抗体及其用途 | |
| HK1177422B (en) | Antibody fc mutants with ablated effector functions | |
| HK1177422A (en) | Antibody fc mutants with ablated effector functions | |
| NZ767672A (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
| KR20120092767A (ko) | 인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 |